{"id":"rucacuzumab-plus-standard-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking C1q, rucacuzumab prevents activation of the classical complement cascade, which is implicated in various autoimmune and inflammatory conditions. When combined with standard therapy, it aims to reduce complement-driven pathology while allowing standard treatments to work synergistically. This approach is particularly relevant in conditions where complement activation contributes to disease progression.","oneSentence":"Rucacuzumab is a monoclonal antibody that binds to complement component C1q to inhibit the classical complement pathway, reducing inflammatory and immune-mediated tissue damage.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:06:25.898Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lupus nephritis (in combination with standard therapy)"}]},"trialDetails":[{"nctId":"NCT07466251","phase":"PHASE4","title":"PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-09-01","conditions":"Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque","enrollment":1212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rucacuzumab plus standard therapy","genericName":"Rucacuzumab plus standard therapy","companyName":"Peking Union Medical College Hospital","companyId":"peking-union-medical-college-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rucacuzumab is a monoclonal antibody that binds to complement component C1q to inhibit the classical complement pathway, reducing inflammatory and immune-mediated tissue damage. Used for Lupus nephritis (in combination with standard therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}